Management and Treatment of Injection Drug Users with Hepatitis C Virus (HCV) Infection and HCV/Human Immunodeficiency Virus Coinfection

ABSTRACT

Injection drug use is the major mode of hepatitis C virus (HCV) transmission in developed countries. Despite this, relatively few current and recovering injection drug users (IDUs) have received HCV treatment. Studies among individuals with a recent history of injection drug use or those receiving drug dependency treatment have provided evidence that these groups can be successfully treated for chronic HCV infection. These studies have provided the impetus to change guidelines for treatment of current and recovering IDUs, with a move toward individualized HCV treatment assessment and the removal of defined periods of illicit drug use abstinence. Strategies to improve access to HCV treatment for current and recovering IDUs include drug dependency treatment education and training for hepatologists and other HCV treatment physicians, HCV treatment education and training for addiction medicine physicians, development of multidisciplinary clinics, and peer-based eduction and support for individuals considering and receiving HCV treatment.

KEYWORDS

Hepatitis C - HIV/HCV coinfection - injection drug users

REFERENCES

• 1 Wasley A, Alter M J. Epidemiology of hepatitis C: geographic differences and temporal trends.  Semin Liver Dis. 2000;  20 1-16
• 2 Dore G J, Law M, MacDonald M, Kaldor J M. Epidemiology of hepatitis C virus infection in Australia.  J Clin Virol. 2003;  26 171-184
• 3 Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L. Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature.  Epidemiol Infect. 2002;  129 577-585
• 4 Steffen T, Blattler R, Gutzwiller F, Zwahlen M. HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme.  Eur J Public Health. 2001;  11 425-430
• 5 Hagan H, Des Jarlais D C. HIV and HCV infection among injecting drug users.  Mt Sinai J Med. 2000;  67 423-428
• 6 McCarthy J J, Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications.  J Addict Dis. 2001;  20 19-31
• 7 Garfein R S, Doherty M C, Monterroso E R, Thomas D L, Nelson K E, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users.  J Acquir Immune Defic Syndr Hum Retrovirol. 1998;  18(suppl 1) 11-19
• 8 Quaglio G, Lugoboni F, Pajusco B et al.. Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy.  Clin Infect Dis. 2003;  37 33-40
• 9 MacDonald M A, Wodak A D, Dolan K A, van Beek I, Cunningham P H, Kaldor J M. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. Collaboration of Australian NSPs.  Med J Aust. 2000;  172 57-61
• 10 Thomas D L, Vlahov D, Solomon L et al.. Correlates of hepatitis C virus infections among injection drug users.  Medicine (Baltimore). 1995;  74 212-220
• 11 Law M G. Modelling the hepatitis C virus epidemic in Australia. Hepatitis C Virus Projections Working Group.  J Gastroenterol Hepatol. 1999;  14 1100-1107
• 12 National Institues of Health . Management of hepatitis C. NIH Consensus Statement 1997.  Available at:http://odp.od.nih.gov/consensus/cons/105/105_intro.htm , Accessed September 20 2004; 
• 13 National Institutes of Health Consensus Development Conference Statement . Management of hepatitis C: June 10-12, 2002.  Hepatology. 2002;  36(suppl 1) S3-S20
• 14 Strader D B, Wright T, Thomas D L, Seeff L B. Diagnosis, management, and treatment of hepatitis C.  Hepatology. 2004;  39 1147-1171
• 15 Manns M P, McHutchison J G, Gordon S C et al.. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.  Lancet. 2001;  358 958-965
• 16 Fried M W, Shiffman M L, Reddy K R et al.. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.  N Engl J Med. 2002;  347 975-982
• 17 Poynard T, Marcellin P, Lee S S et al.. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).  Lancet. 1998;  352 1426-1432
• 18 McHutchison J G, Gordon S C, Schiff E R et al.. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.  N Engl J Med. 1998;  339 1485-1492
• 19 Sylvestre D L. Treating hepatitis C in methadone maintenance patients: an interim analysis.  Drug Alcohol Depend. 2002;  67 117-123
• 20 Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users.  Hepatology. 2001;  34 188-193
• 21 Edlin B R. Prevention and treatment of hepatitis C in injection drug users.  Hepatology. 2002;  36(suppl 1) S210-S219
• 22 Hepatitis C infection and substance abuse: Medical management and developing models of integrative care.  Proc Clin Infect Dis. 2005;  40(suppl 5) , in press
• 23 Stoove M A, Gifford S M, Dore G J. The impact of injecting drug use on hepatitis C-related referral and treatment.  Drug Alcohol Depend. 2005;  77 81-86
• 24 Fleming C A, Craven D E, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment.  Clin Infect Dis. 2003;  36 97-100
• 25 Crofts N, Aitken C K. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995.  Med J Aust. 1997;  167 17-20
• 26 van Beek I, Dwyer R, Dore G J, Luo K, Kaldor J M. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study.  BMJ. 1998;  317 433-437
• 27 Hahn J A, Page-Shafer K, Lum P J et al.. Hepatitis C virus seroconversion among young injection drug users: relationships and risks.  J Infect Dis. 2002;  186 1558-1564
• 28 Crofts N, Hopper J L, Bowden D S, Breschkin A M, Milner R, Locarnini S A. Hepatitis C virus infection among a cohort of Victorian injecting drug users.  Med J Aust. 1993;  159 237-241
• 29 NCHECR. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2002. Sydney; National Centre in HIV Epidemiology and Clinical Research (NCHECR), The University of New South Wales 2002
• 30 Hagan H, McGough J P, Thiede H, Weiss N S, Hopkins S, Alexander E R. Syringe exchange and risk of infection with hepatitis B and C viruses.  Am J Epidemiol. 1999;  149 203-213
• 31 MacDonald M, Law M, Kaldor J M, Hales J, Dore G J. Effectiveness of needle and syringe programmes for preventing HIV transmission.  Int J Drug Policy. 2003;  14 353-357
• 32 Crofts N, Aitken C K, Kaldor J M. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not.  Med J Aust. 1999;  170 220-221
• 33 Micallef J, Kaldor J, Dore G. Estimation of progression to chronic hepatitis C: a meta-analysis. Paper presented at: 11th International Symposium on Viral Hepatitis and Liver Disease in Sydney Australia; April 1 2003: 6-10
• 34 Villano S A, Vlahov D, Nelson K E, Cohn S, Thomas D L. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection.  Hepatology. 1999;  29 908-914
• 35 Freeman A J, Dore G J, Law M G et al.. Estimating progression to cirrhosis in chronic hepatitis C virus infection.  Hepatology. 2001;  34(4 pt 1) 809-816
• 36 Dore G J, Freeman A J, Law M, Kaldor J M. Natural history models for hepatitis C-related liver disease: different disease progression parameters for different settings.  Antivir Ther. 2003;  8 365-372
• 37 Thomas D L, Astemborski J, Rai R M et al.. The natural history of hepatitis C virus infection: host, viral, and environmental factors.  JAMA. 2000;  284 450-456
• 38 Graham C S, Baden L R, Yu E et al.. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.  Clin Infect Dis. 2001;  33 562-569
• 39 Goedert J J, Eyster M E, Lederman M M et al.. End-stage liver disease in persons with hemophilia and transfusion-associated infections.  Blood. 2002;  100 1584-1589
• 40 Benhamou Y, Bochet M, Di Martino V et al.. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.  Hepatology. 1999;  30 1054-1058
• 41 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.  Lancet. 1997;  349 825-832
• 42 Freeman A J, Law M G, Kaldor J M, Dore G J. Predicting progression to cirrhosis in chronic hepatitis C virus infection.  J Viral Hepat. 2003;  10 285-293
• 43 Gordon S C, Elloway R S, Long J C, Dmuchowski C F. The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use.  Hepatology. 1993;  18 1338-1343
• 44 Rai R, Wilson L E, Astemborski J et al.. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users.  Hepatology. 2002;  35 1247-1255
• 45 Davis G L, Rodrigue J R. Treatment of chronic hepatitis C in active drug users.  N Engl J Med. 2001;  345 215-217
• 46 Van Thiel D H, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse.  Am J Gastroenterol. 2003;  98 2281-2288
• 47 Schaefer M, Schmidt F, Folwaczny C et al.. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.  Hepatology. 2003;  37 443-451
• 48 Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance.  Hepatology. 2004;  40 120-124
• 49 Neri S, Bruno C M, Abate G et al.. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b.  Clin Ther. 2002;  24 1627-1635
• 50 Matthews G, Kronrborg I J, Dore G J. Treatment for hepatitis C virus current injection drug users in Australia.  Clin Infect Dis. 2005;  40(suppl 5) , in press
• 51 Jaeckel E, Cornberg M, Wedemeyer H et al.. Treatment of acute hepatitis C with interferon alfa-2b.  N Engl J Med. 2001;  345 1452-1457
• 52 Kamal S M, Ismail A, Graham C S et al.. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.  Hepatology. 2004;  39 1721-1731
• 53 Alberti A, Boccato S, Vario A, Benvegnu L. Therapy of acute hepatitis C.  Hepatology. 2002;  36(suppl 1) 195-200
• 54 NCHECR. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2003. Sydney; National Centre in HIV Epidemiology and Clinical Research (NCHECR), The University of New South Wales 2003
• 55 Doab A, Treloar C, Dore G J. Knowledge and attitude about treatment for hepatitis C virus infection, and barriers to treatment among current injection drug users in Australia.  Clin Infect Dis. 2005;  40(suppl 5) , in press
• 56 Stein M D, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment.  Drug Alcohol Depend. 2001;  61 211-215
• 57 Anti-Discrimination Board of New South Wales . C-change: the report of the enquiry into hepatitis C related discrimination.  Anti-Discrimination Board of New South Wales. Available at: http://www.lawlink.nsw.gov.au/adb.nsf/pages/hepcreport Accessed March 2004; 
• 58 McNally S, Pitts M, Temple-Smith M. Now, later or never: when to refer a patient with hepatitis C. Paper presented at: 4th Australasian Conference on Hepatitis C, 2004 (abstract 65A) Canberra, Astralia;
• 59 Falck-Ytter Y, Kale H, Mullen K D, Sarbah S A, Sorescu L, McCullough A J. Surprisingly small effect of antiviral treatment in patients with hepatitis C.  Ann Intern Med. 2002;  136 288-292
• 60 Zickmund S, Hillis S L, Barnett M J, Ippolito L, LaBrecque D R. Hepatitis C virus-infected patients report communication problems with physicians.  Hepatology. 2004;  39 999-1007
• 61 Crofts N, Nigro L, Oman K, Stevenson E, Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users.  Addiction. 1997;  92 999-1005
• 62 Selvey L A, Denton M, Plant A J. Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: factors influencing hepatitis C serostatus.  Aust N Z J Public Health. 1997;  21 102-104
• 63 Alter M J, Margolis H S, Krawczynski K et al.. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.  N Engl J Med. 1992;  327 1899-1905
• 64 Mehta S H, Cox A, Hoover D R et al.. Protection against persistence of hepatitis C.  Lancet. 2002;  359 1478-1483
• 65 Micallef J, Jauncey M, Amin J et al.. Hepatitis C virus reinfection within a cohort of injecting drug users.  Hepatology. 2003;  38(suppl 1) 266A
• 66 Bhattacharya R, Shuhart M C. Hepatitis C and alcohol: interactions, outcomes, and implications.  J Clin Gastroenterol. 2003;  36 242-252
• 67 Wiley T E, McCarthy M, Breidi L, Layden T J. Impact of alcohol on the histological and clinical progression of hepatitis C infection.  Hepatology. 1998;  28 805-809
• 68 Golub E T, Latka M, Hagan H et al.. Screening for Depressive Symptoms Among HCV-Infected Injection Drug Users: Examination of the Utility of the CES-D and the Beck Depression Inventory.  J Urban Health. 2004;  81 278-290
• 69 Gleason O C, Yates W R, Isbell M D, Philipsen M A. An open-label trial of citalopram for major depression in patients with hepatitis C.  J Clin Psychiatry. 2002;  63(3) 194-198
• 70 Kraus M R, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.  Aliment Pharmacol Ther. 2002;  16 1091-1099
• 71 Musselman D L, Lawson D H, Gumnick J F et al.. Paroxetine for the prevention of depression induced by high-dose interferon alfa.  N Engl J Med. 2001;  344 961-966
• 72 Khan M H, Farrell G C, Byth K et al.. Which patients with hepatitis C develop liver complications?.  Hepatology. 2000;  31 513-520
• 73 Rey D, Carrieri M P, Spire B et al.. Factors associated with liver biopsy performance in HCV-HIV coinfected injecting drug users with HCV viremia: results from a five-year longitudinal assessment.  J Urban Health. 2004;  81 48-57
• 74 Poynard T, Imbert-Bismut F, Ratziu V et al.. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial.  J Viral Hepat. 2002;  9 128-133
• 75 Imbert-Bismut F, Ratziu V, Pieroni L et al.. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.  Lancet. 2001;  357 1069-1075
• 76 Sylvestre D L. The impact of negative prognostic factors on hepatitis C treatment in recovering injection drug users.  Hepatology. 2002;  36(4 pt 2) 223A
• 77 Sylvestre D L. Injection drug use and hepatitis C: from transmission to treatment.  Psychiatr Ann. 2003;  33 377-382
• 78 Kresina T F, Normand J, Khalsa J, Mitty J, Flanigan T, Francis H. Addressing the need for treatment paradigms for drug-abusing patients with multiple morbidities.  Clin Infect Dis. 2004;  38(suppl 5) S398-S401
• 79 Krantz M J, Mehler P S. Treating opioid dependence. Growing implications for primary care.  Arch Intern Med. 2004;  164 277-288
• 80 Bouhnik A D, Chesney M, Carrieri P et al.. Nonadherence among HIV-infected injecting drug users: the impact of social instability.  J Acquir Immune Defic Syndr. 2002;  31(suppl 3) S149-S153
• 81 Escaffre N, Morin M, Bouhnik A D et al.. Injecting drug users' adherence to HIV antiretroviral treatments: physicians' beliefs.  AIDS Care. 2000;  12 723-730
• 82 Moatti J P, Carrieri M P, Spire B, Gastaut J A, Cassuto J P, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group.  AIDS. 2000;  14 151-155
• 83 Wood E, Montaner J S, Yip B et al.. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.  Can Med Assoc J. 2003;  169 656-661
• 84 Conway B, Prasad J, Reynolds R et al.. Directly observed therapy for the management of HIV-infected patients in a methadone program.  Clin Infect Dis. 2004;  38(suppl 5) S402-S408
• 85 Lucas G M, Weidle P J, Hader S, Moore R D. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study.  Clin Infect Dis. 2004;  38(suppl 5) S409-S413
• 86 Altice F L, Mezger J A, Hodges J et al.. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication.  Clin Infect Dis. 2004;  38(suppl 5) S376-S387
• 87 Butler T G, Dolan K A, Ferson M J, McGuinness L M, Brown P R, Robertson P W. Hepatitis B and C in New South Wales prisons: prevalence and risk factors.  Med J Aust. 1997;  166 127-130
• 88 Baillargeon J, Wu H, Kelley M J, Grady J, Linthicum L, Dunn K. Hepatitis C seroprevalence among newly incarcerated inmates in the Texas correctional system.  Public Health. 2003;  117 43-48
• 89 Vlahov D, Nelson K E, Quinn T C, Kendig N. Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland.  Eur J Epidemiol. 1993;  9 566-569
• 90 Sterling R K, Hofmann C M, Luketic V A et al.. Treatment of chronic hepatitis C virus in the Virginia department of corrections: can compliance overcome racial differences to response?.  Am J Gastroenterol. 2004;  99 866-872
• 91 Allen S A, Spaulding A C, Osei A M, Taylor L E, Cabral A M, Rich J D. Treatment of chronic hepatitis C in a state correctional facility.  Ann Intern Med. 2003;  138 187-190
• 92 Villano S A, Vlahov D, Nelson K E, Lyles C M, Cohn S, Thomas D L. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland.  J Clin Microbiol. 1997;  35 3274-3277
• 93 Amin J, Kaye M, Skidmore S, Pillay D, Cooper D A, Dore G J. HIV and hepatitis C coinfection within the CAESAR study.  HIV Med. 2004;  5 174-179
• 94 Lincoln D, Petoumenos K, Dore G J. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy.  HIV Med. 2003;  4 241-249
• 95 Bonacini M, Lin H J, Hollinger F B. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus.  J Acquir Immune Defic Syndr. 2001;  26 340-344
• 96 George S L, Gebhardt J, Klinzman D et al.. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests.  J Acquir Immune Defic Syndr. 2002;  31 154-162
• 97 Thio C L, Nolt K R, Astemborski J, Vlahov D, Nelson K E, Thomas D L. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals.  J Clin Microbiol. 2000;  38 575-577
• 98 Sherman K E, O'Brien J, Gutierrez A G et al.. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections.  J Clin Microbiol. 1993;  31 2679-2682
• 99 Eyster M E, Fried M W, Di Bisceglie A M, Goedert J J. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study.  Blood. 1994;  84 1020-1023
• 100 Thomas D L, Shih J W, Alter H J et al.. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users.  J Infect Dis. 1996;  174 690-695
• 101 Anonymous . 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.  HIV Clin Trials. 2001;  2 493-554
• 102 Eyster M E, Diamondstone L S, Lien J M, Ehmann W C, Quan S, Goedert J J. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study.  J Acquir Immune Defic Syndr. 1993;  6 602-610
• 103 Darby S C, Ewart D W, Giangrande P L et al.. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation.  Lancet. 1997;  350 1425-1431
• 104 Chung R T, Andersen J, Volberding P et al.. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.  N Engl J Med. 2004;  351 451-459
• 105 Torriani F J, Rodriguez-Torres M, Rockstroh J K et al.. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.  N Engl J Med. 2004;  351 438-450
• 106 Bräu N. Treatment of chronic hepatitis C in HIV/HCV-coinfected patients in the era of pegylated interefron and ribavirin.  Semin Liver Dis. 2005;  25 33-51
• 107 Benhamou Y, Di Martino V, Bochet M et al.. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.  Hepatology. 2001;  34 283-287
• 108 Qurishi N, Kreuzberg C, Luchters G et al.. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.  Lancet. 2003;  362 1708-1713